Alto Neuroscience, Inc. (ANRO) 股票分析

公司概述

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical entity within the United States, focusing on the development of novel therapeutics for neurological and psychiatric conditions. The company is situated in the Healthcare sector, specifically within the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant research and development expenditures before achieving commercial viability. The firm employs a workforce of 68 individuals and maintains a market capitalization of $715.58 million, while reported annual revenue figures are not currently disclosed in available data. These valuation metrics, combined with the absence of disclosed revenue, indicate that the company's market value is primarily derived from the potential of its product pipeline, including ALTO-100 for bipolar depression and ALTO-300, a small molecule melatonin, rather than established commercial sales.

财务健康

The company reports a net income of $-63,238,000 and an EBITDA of $-65,703,000 over the trailing twelve months, while revenue data is not available; the substantial gap between revenue and net income, coupled with the lack of revenue figures, suggests that the company is in a pre-revenue or late-stage development phase where operating expenses and R&D costs are consuming capital without corresponding sales income. Free cash flow stands at $-33,950,624, indicating that the company is burning cash to fund its clinical trials and operational activities, which necessitates access to external capital markets or existing cash reserves to maintain financial flexibility. The gross margin, operating margin, and profit margin are all recorded at 0.0%, reflecting a typical characteristic of early-stage biotechnology firms that have not yet generated significant sales volume to offset high fixed development costs. On the balance sheet, the company holds $176.48 million in cash against $23.96 million in debt, resulting in a debt-to-equity ratio of 15.85, which implies a leveraged capital structure where equity capital is significantly larger than debt obligations to fund operations. Despite the leverage, the current ratio is exceptionally high at 15.69, signaling robust short-term liquidity and a strong ability to meet immediate financial obligations without distress. Return on Equity is -41.8% and Return on Assets is -22.9%, metrics that reveal that management effectiveness is currently measured by the preservation of capital and the execution of clinical milestones rather than the generation of shareholder returns from profitable operations.

估值评估

The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is listed as -9.85, implying that the market expects the company to remain unprofitable in the near term or that valuation models are relying on revenue-based or pipeline-specific metrics rather than earnings power. The price-to-book ratio stands at 4.73, indicating that the market values the company at a significant premium over its net book value, likely driven by the intangible value of its intellectual property and clinical-stage assets rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio are not applicable due to missing revenue data, and the EV/EBITDA is -8.57, which suggests that traditional enterprise value multiples are distorted by the company's negative earnings position. The stock has traded between a 52-week low of $1.90 and a 52-week high of $25.17, placing the current market price in a wide trading range that reflects high investor sentiment volatility regarding the company's clinical outcomes. With a beta of 2.06, the stock exhibits price volatility that is more than double that of the broader market, indicating that the asset is highly sensitive to market movements and specific biotech sector news.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as not applicable, preventing a direct comparison of earnings growth rates relative to revenue expansion at this stage of the company's lifecycle. As a non-dividend payer, the company maintains a dividend yield of not applicable and a payout ratio of 0.0%, meaning that any generated earnings or cash flow are entirely reinvested into research, development, and clinical operations rather than distributed to shareholders. The absence of a dividend program aligns with the strategic necessity for biotechnology firms to allocate all available capital toward advancing their product pipeline to regulatory approval. Consequently, the overall growth and income profile is defined entirely by the potential future commercialization of its drug candidates rather than current dividend income or historical earnings growth.